In lung cancer, miR-494 targets BIM to modulate TRAIL-induced apoptosis.23 Although in human cholangiocarcinoma, miR-494 has a global regulatory role in cell cycle progression causing G2/M arrest.29 In chondrosarcoma, miR-494 targets SOX9 to inhibit cell proliferation and invasion in vitro.30 In pancreatic cancer, miR-494 is significantly downregulated in pancreatic cancer tissue and is correlated with tumor progression and might be an independent, poor prognostic factor for patient with pancreatic cancer.31 From that we see in most of human cancer, miR-494 acts as an antitumor-microRNA. Here, SOX9 is linked to cholangiocarcinoma.